MétaCan
Menu
Back to cohort
Record W4280609905 · doi:10.1016/j.esmoop.2022.100483

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force

2022· article· en· W4280609905 on OpenAlexaff
Evangelia Razis, M.J. Escudero, Carlo Palmieri, Volkmar Müller, Rupert Bartsch, Giovanna Rossi, Simon Peter Gampenrieder, Hans‐Christian Kolberg, Nicholas Zdenkowski, Michel Pavic, Roisín M. Connolly, Laurent Rosset, J. Arcuri, Hans Tesch, Carlos Vallejos, Javier Retamales, Antonino Musolino, Lucia Del Mastro, C. Christodoulou, Stefan Aebi, Shani Paluch–Shimon, Sudeep Gupta, Shinji Ohno, Iain R. Macpherson, Maria Ekholm, Khalil Zaman, María Vidal, Camille Chakiba, Debora Fumagalli, Anna Thulin, Isabell Witzel, Nuria Kotecki, Miguel Gil‐Gil, Barbro Linderholm

Bibliographic record

VenueESMO Open · 2022
Typearticle
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsUniversité de Sherbrooke
FundersGenentechIpsenServierEuropean Organisation for Research and Treatment of CancerEisaiDaiichi-SankyoAstellas PharmaMylanGenomic HealthF. Hoffmann-La RocheChugai PharmaceuticalSeagenGilead SciencesDaiichi Sankyo EuropeSanofiAmgenPfizerLes Laboratories Pierre FabreAstraZenecaEli Lilly and Company
KeywordsBreast cancerMedicineCancerInternal medicineOncology

Abstract

fetched live from OpenAlex

BACKGROUND: Carcinomatous meningitis (CM) is a severe complication of breast cancer. The Breast International Group (BIG) carried out a survey to describe the approach to CM internationally. PATIENTS AND METHODS: A questionnaire on the management of CM was developed by the Brain Metastases Task Force of BIG and distributed to its groups, requesting one answer per group site. RESULTS: A total of 241 sites responded, 119 from Europe, 9 from North America, 39 from Central/South America, 58 from Asia, and 16 in Australia/New Zealand, with 24.5% being general hospitals with oncology units, 44.4% university hospitals, 22.4% oncology centers, and 8.7% private hospitals. About 56.0% of sites reported seeing <5 cases annually with 60.6% reporting no increase in the number of cases of CM recently. Nearly 63.1% of sites investigate for CM when a patient has symptoms or radiological evidence, while 33.2% investigate only for symptoms. For diagnosis, 71.8% of sites required a positive cerebrospinal fluid cytology, while magnetic resonance imaging findings were sufficient in 23.7% of sites. Roughly 97.1% of sites treat CM and 51.9% also refer patients to palliative care. Intrathecal therapy is used in 41.9% of sites, mainly with methotrexate (74.3%). As many as 20 centers have a national registry for patients with breast cancer with central nervous system metastases and of those 5 have one for CM. Most (90.9%) centers would be interested in participating in a registry as well as in studies for CM, the latter preferably (62.1%) breast cancer subtype specific. CONCLUSIONS: This is the first study to map out the approach to CM from breast cancer globally. Although guidelines with level 1 evidence are lacking, there is a high degree of homogeneity in the approach to CM globally and great interest for conducting studies in this area.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.015
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.021
Threshold uncertainty score0.044

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.015
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0020.004
Science and technology studies0.0010.001
Scholarly communication0.0010.002
Open science0.0010.002
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.319
Teacher spread0.304 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueESMO OpenSame topicBrain Metastases and TreatmentFrench-language works237,207